AtriCure, Inc.ATRCNASDAQ

Want to monitor ATRC?

Get notified when price crosses targets, volume spikes, or RSI hits oversold

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide.

Manufacturing

Surgical and Medical Instrument Manufacturing

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance

Alerts

Key Statistics

About

News

Invitation Homes And American Homes 4 Rent Just Got Interesting

Goldman Sachs Soars on Q4 Post, Strong Investment Banking Outlook

GPAC Announces Annual Security-Based Compensation Grants

Stellus Capital Investment Corporation Announces $0.34 First Quarter 2026 Regular Dividend, Payable Monthly in Increments of $0.1133 in February, March, and April 2026

Fox Went All In on Live Programming. It's Paying Off.

GAUZ Investors Have Opportunity to Lead Gauzy Ltd. Securities Fraud Lawsuit

Xcel Energy 2025 Year End Earnings Conference Call

NuGen Medical Devices Provides 2025 Year End Update on R&D and Strategic Progress

SAGA Metals Announces Additional Assay Results from Drilling at Trapper North, Confirming High-Grade Mineralization at Radar Critical Minerals Project in Labrador

Rosen Law Firm Urges Vistagen Therapeutics, Inc. (NASDAQ: VTGN) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Neste: 2025's Tremendous Returns Are The Start Of Recovery

Sandisk: The NAND Trade Is Getting Crowded Heading Into Q2 Earnings

LibertyStream Announces Non-Brokered LIFE Offering of up to $10,000,000

Exclusive: US moving fast to expand Chevron's Venezuela license, Energy Secretary Wright tells Reuters

Western Uranium & Vanadium Announces Securities Transactions

Silver North Announces Further Upsize of Brokered LIFE Private Placement for Gross Proceeds of up to C$10.6 Million

Wedbush's Alicia Reese looks ahead to Netflix's Q4 results

Vertiqal Studios Announces Sale of Luminosity Gaming

Christina Lake Cannabis Announces Sale of Bare Land

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)